Vivani Medical Mergers and Acquisitions Presentation Deck

Proposed First in Human Trial: LIBERATE-1 Primary Objectives: Safety/tolerability assessment and full PK characterization Secondary Objective: Evaluate change from baseline in glycemic control (HbA1c) Key Inclusion/Exclusion Criteria T2DM and HbA1c 26.5% and <10.0% . On non-exenatide GLP-1 therapy (discontinued upon enrollment) . May be taking their GLP-1 in combination with up to 2 of the following: metformin, TZD, SGLT-2 inhibitor, or DPP-4 inhibitor Excluded: SU, insulin Randomize NPM-119 Low Dose (N=20) NPM-119 High Dose (N=20) Bydureon BCise 2mg/week (N=20) 12 Weeks T2DM: Type 2 Diabetes Mellitus; TZD: Thiazolidinedione; SGLT-2: Sodium-glucose cotransporter-2; DPP-4: Dipeptidyl peptidase 4; SU: Sulfonylurea 19

View entire presentation